Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
+$0.01 today
- Market cap
- $113.54M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
Volume 7.09M
Average 4.03M
AKBA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Akebia Therapeutics, Inc.NASDAQ: AKBA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows in line with its trailing trend
Q1 FY2026 stock-based compensation of $3.67M rose 67.7% year over year, in line with the +67.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 14.7% from the prior quarter. Over 3 fiscal years it compounded at -14.2% a year.
Context
- Stock-based compensation amounted to 4.8% of revenue in FY2025, unchanged from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +67.7% toward the trailing-twelve-month pace of +67.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 11.28M USD
- Year-over-year change
- +45.1%
- 4-year CAGR
- -16.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.28M | +45.1% |
| FY2024 | 2024-12-31 | 7.78M | -16.6% |
| FY2023 | 2023-12-31 | 9.32M | -47.8% |
| FY2022 | 2022-12-31 | 17.85M | -21.5% |
| FY2021 | 2021-12-31 | 22.74M | — |
Stock-Based Compensation vs competitors
How AKBA compares with its peers on the latest reported figures
- AKBA's LTM Mar 2026 stock-based compensation of $12.76M is the 6th largest of the 10 companies compared; the peer median is $12.84M.
- Its year-over-year change of +67.9% is the 2nd highest of 9, against a peer median of -18.3%.
- Stock-based compensation amounts to 5.5% of revenue for AKBA, versus a peer median of 16.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.61M | -24.5% | +6.3% | 58.0% | |
| LTM Mar 2026 | $19.48M | -28.2% | +8.7% | 22.1% | |
| LTM Mar 2026 | $14.45M | -16.0% | -37.2% | 26.0% | |
| LTM Mar 2026 | $13.21M | -40.1% | — | — | |
| LTM Mar 2026 | $12.84M | +21.4% | +0.9% | 4.3% | |
| LTM Mar 2026 | $12.76M | +67.9% | -14.2% | 5.5% | |
| LTM Mar 2026 | $12.62M | -20.6% | +43.3% | 10.3% | |
| LTM Mar 2026 | $10.93M | +20.5% | +16.2% | — | |
| LTM Mar 2026 | $6.73M | +88.8% | +25.6% | — | |
| LTM Dec 2025 | $5.38M | — | — | 4.6% | |
| Peer median (excluding AKBA) | $12.84M | -18.3% | +8.7% | 16.2% | |
Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (282.02M) | (92.56M) | (51.93M) | (69.41M) | (5.35M) |
| Depreciation & Amortization | 36.13M | 37.7M | 41.85M | 37.5M | 1.27M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.74M | 17.85M | 9.32M | 7.78M | 11.28M |
| Change in Working Capital | (105.61M) | (1.44M) | (20.73M) | (39.68M) | 16.47M |
| Accounts Receivables | (24.03M) | 11.7M | 994K | 4.05M | (14.14M) |
| Inventory | (24.95M) | 19.79M | (2.54M) | (28.4M) | (23.13M) |
| Accounts Payables | (11.74M) | 1.5M | (5.24M) | (1.36M) | 3.08M |
| Other Working Capital | (44.9M) | (34.42M) | (13.94M) | (13.96M) | 50.66M |
| Other Non-Cash Items | 98.54M | (34.7M) | (1.9M) | 23.15M | 44.31M |
| Operating Cash Flow | (252.97M) | (73.15M) | (23.38M) | (40.66M) | 67.99M |
| Capital Expenditures | (59K) | (114K) | 0 | (33K) | (291K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 40M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (7.93M) |
| Investing Cash Flow | 39.94M | (114K) | 0 | (33K) | (7.93M) |
| Debt Repayment | 44.78M | (33M) | (32M) | 7.9M | 4.63M |
| Common Stock Issued | 88.95M | 7.53M | 6.79M | 42.65M | 68.36M |
| Common Stock Repurchased | 0 | 0 | 0 | (1.27M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 40.07M | 1K | 385K | (63K) |
| Financing Cash Flow | 133.73M | 14.6M | (25.21M) | 49.66M | 72.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (79.29M) | (58.67M) | (48.59M) | 8.97M | 132.99M |
| Free Cash Flow | (253.02M) | (73.27M) | (23.38M) | (40.69M) | 67.99M |
Akebia Therapeutics, Inc.
NASDAQ:AKBA
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.